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Edited by Jeusus AvilaAbstract The 29-residue peptide hormone glucagon has been
used as a model system for the study of amyloid-like ﬁbrils.
Atomic force microscopy (AFM) studies have detected putative
oligomeric species during this lag phase, but this has not been
conﬁrmed by any spectroscopic technique. Here we use an at-
tached pyrene group to detect association (excimer formation)
between individual glucagon molecules. Our data show that exci-
mer formation precedes ﬁbrillation both at diﬀerent pHs and
with sulfate, and support our original proposal that glucagon ﬁ-
bril formation is preceded by oligomer formation. We suggest
that pyrene-labelling may be a useful way to monitor oligomer
formation during protein ﬁbrillation.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Excimer1. Introduction
Formation of protein ﬁbrils is thought to occur via a nucle-
ation-dependent elongation mechanism, where the rate-limiting
step is the formation of a thermodynamically unfavorable nu-
cleus [1]. When observed over time, such mechanisms often
have a sigmoidal shape with a characteristic lag-phase, during
which the concentration of ﬁbrils is below the detection limit
[2]. Frequently oligomeric species accumulate during this lag-
phase, and there is an ongoing debate as to whether or not these
oligomers are involved in the ﬁbril formation [3]. For some pro-
teins, reports indicate that oligomers may be directly involved
as intermediate building blocks in the formation of ﬁbrils [4],
for others elongation of amyloid ﬁbrils proceeds via monomers
[5]. However, it has recently become apparent that a protein
may form several amyloid structures, diﬀering at the level of
molecular packing, and that this occurs via distinct mechanisms
[6]. Thus observation of ﬁbrillation without accumulation ofAbbreviations: G, glucagon; PG, N-terminal pyrene modiﬁed gluca-
gon; ThT, thioﬂavin T; DLS, dynamic light scattering; AFM, atomic
force microscopy; RH, hydrodynamic radius; GdmCl, Guanidinium
Chloride; FRET, Fo¨rster resonance energy transfer; TEM, transmis-
sion electron microscopy; RFU, relative ﬂuorescence units
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doi:10.1016/j.febslet.2008.03.017oligomers under one set of experimental conditions does not ex-
clude the possibility that oligomeric intermediates could be
important under a diﬀerent set of conditions [7].
Fibrillation is usually followed semi-quantitively by thioﬂa-
vin T (ThT) ﬂuorescence [8], which does not detect oligomers,
presumably because of the lack of repetitive structures which
provide the extended binding sites that are the hallmarks of ﬁ-
brils [9]. Instead, oligomers are usually identiﬁed in a non-
quantitative fashion by size exclusion chromatography or by
direct visualization with by atomic force- or electron micros-
copy. An alternative is to use small angle X-ray scattering.
The outcome is potentially very informative structurally and
may directly link oligomer accumulation with ﬁbril elongation
[10], but the approach preferably requires access to synchro-
tron radiation facilities for optimal results, and is computa-
tionally intensive, requiring months of work for proper
analysis. In addition, it is often performed at high protein con-
centrations which may not always be physiologically relevant
and actually promote the formation of oligomers. An alterna-
tive and more functional assay is to test for the aggregates
ability to permeabilize synthetic phospholipids membranes
and release encapsulated material, since oligomers are ob-
served to be much better at this than monomers and ﬁbrils
[11]. However, this approach is indirect, requiring a certain
functionality that not all oligomers may possess and is quite la-
bour-intensive. It would be good to have an alternative and
more direct approach to identify oligomers.
A recent study used the increase in anisotropy of an attached
ﬂuorophore to register formation of protein aggregates [12]. In
that elegant approach, aggregation was measured by the de-
crease in molecular freedom associated with aggregation. Here
we describe the use of pyrene-labelling and monitoring of exci-
mer formation to follow the formation of pre-ﬁbrillar oligo-
mers. Pyrene can form excited dimers or excimers when two
pyrene molecules come in proximity and stack together. This
changes the ﬂuorescent properties of the pyrene. The mono-
mers show emission at two distinct bands at 375 and 398 nm
when excited at 339 nm, whereas the excimer emits mainly
around 470 nm. Pyrene excimer formation has previously been
used to verify that two independent molecules in a ﬁbril are in
close proximity [13], and to identify sites of intermolecular
contacts [14]. As model system for our approach, we use the
29-residue hormone glucagon (G), whose ﬁbrillation behavior
we have previously described in detail using conventional ThT
ﬂuorescence [15–17], atomic force microscopy (AFM) [3] and a
quartz crystal microbalance [18]. Using the pyrene approach toblished by Elsevier B.V. All rights reserved.
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falls: Glucagon is a prime example of ﬁbrillar polymorphism,
in which small changes in solvent conditions can alter the
structure of the ensuing ﬁbril [19], and addition of a large
hydrophobic molecule at the N-terminus could be expected
to aﬀect the aggregation process profoundly. As part of our
characterization, we therefore describe how to optimize the
use of pyrene-labelled glucagon to minimize such artifacts.2. Materials and methods
2.1. Peptides and chemicals
Pharmaceutical-grade glucagon (98.9% pure) was puriﬁed by Novo
Nordisk A/S (Bagsværd, Denmark). Pyrene-maleimide-Mpr-Glucagon
(>95% pure was purchased from Biosyntan GmbH (Berlin, Ger-
many)). The pyrene-maleimide is coupled N-terminally on the gluca-
gon via the 3-mercapto-propionic acid. The concentration of
glucagon was measured using a calculated extinction coeﬃcient E
(280 nm, 1 cm, 1 g/l, 6 M GdmCl, pH 6.5) = 2.369. The concentration
of pyrene modiﬁed glucagon was assessed via the weighed peptide and
a pyrene absorbance measurement using the internal extinction coeﬃ-
cient on an NanoDrop ND-1000 UV–vis Spectrophotometer (Nano-
Drop Technologies, USA). Glucagon supplied by Novo Nordisk A/S
as a powder was readily dissolvable in 10 mM HCl at a concentration
of 10 g/l by careful pipetting to dissolve visible clumps. The purchased
pyrene modiﬁed glucagon was dissolved in 1 volume 10 mM HCl + 1
volume of buﬀer to a concentration of 5 g/l, also using careful pipetting
to dissolve visible clumps. All other chemicals were standard grade
supplied by Sigma.
2.2. Dynamic light scattering
This was measured on a PD2000DLS Plus instrument (Postnova
Analytics, Germany). A scattering angle of 90 was used for the mea-
surements and a mass normalization function was employed to obtain
a concentration-normalized hydrodynamic radius RH.
2.3. Fluorescence
Fluorescence emission spectra were recorded on a Cary Eclipse (Var-
ian Inc., USA) every 5 min using 0.5 g/l total glucagon including 0.1 g/l
pyrene modiﬁed glucagon in 50 mM glycine pH 2.5. Stirring in the
ﬂuorescence cuvette was at full speed. Excitation wavelengths were
295 nm (emission from 310 to 550 nm) or 339 nm (emission from 350
to 550 nm), respectively, using 2.5 and 5 nm slit widths for excitation
and emission, respectively.
2.4. Plate reader assay
Fresh glucagon and pyrene modiﬁed glucagon stock solutions were
diluted to appropriate concentrations and ratios in appropriate buﬀer
50 mM glycine/HCl (pH 2.5), 5 mM HCl (pH 2.3) with 16 mM NaCl,
10 mMHCl (pH 2.0), 5 mM glycine (pH 9.5) and with varying concen-
trations of sodium sulfate. The sample solutions were transferred to
96-well black Costar polystyrene microtiter plates (cat. no. 3915, Corn-
ing Incorporated) and the plates were sealed using crystal-clear sealing
tape (Hampton research, Aliso Viejo CA). Fluorescence were followed
at 330 and 350 nm (excitation 295 nm) or 375 and 470 nm (excitation
339 nm) on a SpectraMax Gemini XS (Molecular Devices Ltd., UK)
or a Tecan inﬁnite 200 (Tecan Nordic AB, Sweden). Samples were
shaken either 3 s or 5 min before reading every 10 min.3. Results
3.1. Detection of oligomeric species during lag-phase
We have previously demonstrated that the ﬁbrillation of glu-
cagon can be followed using intrinsic ﬂuorescence, by monitor-
ing the blue-shift of Trp25 excited at 295 nm which gives a
simple sigmoidal transition [15]. However, neither the intrinsic
ﬂuorescence nor allowing glucagon to aggregate in the pres-ence of ThT leads to detection of any possible transient oligo-
meric species appearing in the lag-phase. To enhance the
ﬂuorescent properties of possible oligomers, we decided to
use pyrene-labelled glucagon to detect the species in a more di-
rect fashion. Fig. 1A shows a emission spectra of 0.5 g/l total
glucagon (1:5 PG:G) based on excitation of pyrene (339 nm).
After 115 min incubation, there is an increase in ﬂuorescence
emission at 470 nm (excimer) and a decrease in emission at
375 nm (monomer), indicating that pyrene monomers are in-
volved in excimer formation. After 195 min, the peak at
470 nm has decreased to the initial level and the peak at
375 nm has increased signiﬁcantly, which together indicate
that the pyrene groups no longer form excimers. Therien and
Deber showed that the intensity of the excimer peak, provided
excimers still exist, is not signiﬁcantly aﬀected when embedded
in a hydrophobic environment such as detergents, whereas the
monomer band intensity is variable [20]. The changes that we
observe could therefore arise from structural rearrangements
that disrupt the original excimers (leading to a reduction in
excimer ﬂuorescence) and locate the pyrene groups at a hydro-
phobic region (leading to a rise in monomer ﬂuorescence). This
is supported by the observation that glucagon ﬁbrillation is
accompanied by a rise in the ﬂuorescence of the probe ANS,
which is an indication of the formation of hydrophobic regions
(data not shown). Fig. 1B shows an emission spectrum of the
same sample with excitation of tryptophan (295 nm). The ﬁbril
signature, namely an increased ratio between emission at 320
and 350 nm, reaches maximum at 195 min, which is clearly la-
ter than the excimer formation maximum at 115 min in
Fig. 1A. Pyrene can also be detected in Fig. 1B, as the pyrene
is excited by Trp emission through Fo¨rster resonance energy
transfer (FRET).
Optimization of the pyrene approach involved a series of
titrations with variable ratios of labelled and unlabelled gluca-
gon, where the end product was monitored by AFM and trans-
mission electron microscopy (TEM). Fibrillar structures were
formed when the total concentration of PG was lower than
0.2 g/l (Fig. S1). Above this concentration, the visualized end
products proved to be a mixture of ﬁbrils and aggregates
(Fig. S2). Thus, the small change of adding a pyrene to the se-
quence perturbs the ﬁbrillation process, leading to both aggre-
gates and ﬁbrils at concentration above 0.2 g/l modiﬁed
glucagon. Nevertheless, these mixed end products undergo a
similar type of ﬂuorescence changes with regards to pyrene
(excimer/monomer) and tryptophan as the actual ﬁbril formed
at lower PG ratios. Therefore we only focus on data for exper-
iments conducted at less than 0.2 g/l PG. To evaluate whether
PG and glucagon mix indiscriminately to form an integrated
ﬁbril or segregate into separate structures, we compared the
evolution of excimer intensity in 0.1 g/l pure pyrene modiﬁed
glucagon with 0.5 g/l total glucagon containing 0.1 g/l PG. If
mixed ﬁbrils are formed, PG will be diluted out with non-la-
belled glucagon and thus form a much lower excimer level.
In fact we see that the PG-pure ﬁbrils lead to a 10-fold greater
increase in emission than the mixture, supporting the forma-
tion of mixed ﬁbrils Fig 2A. Comparing the emission spectra
at 330 nm of ﬁbril formation of non-labelled glucagon with
(1:10 PG:G) glucagon a clear cis-FRET is seen (Fig. 2B).
The presence of pyrene in the ﬁbril diminishes the emission
at 330 nm, whereas no trans-FRET is observed with pyrene
is solution (data not shown). A similar conclusion can be
drawn from Fig. 1B where pyrene emission signatures are
Fig. 1. Emission spectra taken at diﬀerent time points of the aggregation of 0.5 g/l total glucagon (1:5 PG:G) in 50 mM glycine, pH 2.5 at 25 C with
maximum stirring in the cuvette: (A) Excitation of pyrene at 339 nm; (B) excitation of tryptophan at 295 nm.
Fig. 2. (A) Emission intensity at 470 nm of 0.1 g/l 100% pyrene modiﬁed glucagon (s) and 0.5 g/l total glucagon (1:5 PG:G) (d) both in 50 mM
glycine, pH 2.5 at 25 C. The increase in signal intensities are approx. 50% for 0.1 g/l pyrene modiﬁed glucagon and approx. 5% for 1:5 PG:G. (B)
Emission intensity at 330 nm of (open symbols) 0.5 g/l glucagon and (closed symbols) 0.5 g/l glucagon (1:10 PG:G) both in 50 mM glycine, pH 2.5 at
25 C. The observed variation in triplicates is 20% in intensity and 5% in lag-time.
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more cis-FRET excitation energy available.
Glucagon forms diﬀerent types of ﬁbrils under diﬀerent sol-
vent conditions. For example, the presence of sodium sulfate
can profoundly aﬀect ﬁbril architecture, kinetics of formation
and stability [17]. However, pyrene ﬂuorescence can also be
used to monitor pre-ﬁbrillar events in the presence of sodium
sulfate. Fig. 3 contrasts the time proﬁles for glucagon ﬁbrillat-
ing in glycine pH 2.5 (Fig. 3A) and in 7 mM Na2SO4, pH 2
(Fig. 3B). In both cases, a pre-ﬁbrillar signal increase at
470 nm coincides with a signal decrease at 375 nm. The normal
ﬁbrillation signal (increase in the 330/350 nm ratio for Trp
ﬂuorescence) coincides with the increase in signal increase at
375 nm. Interestingly, ﬁbrillation in Fig. 3A is accompanied
by a temporary decrease in excimer emission followed by a
slow recovery, while the decrease is permanent in Fig. 3B. This
provides further evidence for the diﬀerence in ﬁbril structures
formed under diﬀerent conditions. The phase diagram inserts
highlight that the formation of the excimer preceded the ﬁbril-
lation process.Due to the formation of drying artifacts under low glucagon
concentrations (data not shown), we were unable to visualize
by AFM whether the species identiﬁed at the pre-ﬁbrillar stage
were indeed oligomers as previously reported [3]. However, an
evaluation of the starting material of aggregating samples by
dynamic light scattering (DLS), showed that samples of gluca-
gon and PG:G (1:5) had identical RH during early lag-time.
Previously, we have observed that conditions leading to type
B glucagon ﬁbrils can be preceded by transient type A ﬁbrils
[15]. These transient type A ﬁbrils can be avoided by lowering
the concentration of total glucagon, as phase diagrams of ThT
and Trp ﬂuorescence clearly indicate the presence of only two
spectroscopic diﬀerent species [15]. Similar dilution experi-
ments were made here and in all experiments the pyrene exci-
mer signal preceded the ﬁbrillation (Fig. 4). We conclude that
the excimer signal is not caused by the transient formation of
type A ﬁbrils. Additionally, thermal stability followed by ﬂuo-
rescence (data not shown) also showed that the stability of the
PG:G (1:5) ﬁbrils were comparable with the stability of the ﬁ-
brils formed of pure glucagon, which indicates that the end
Fig. 3. Examples of ﬁbrillation time curves followed by normalized tryptophan ﬂuorescence (ratio of emission at 330 and 350 nm) (h) and pyrene
ﬂuorescence measured at 375 nm (s) and 470 nm (d). The experiments are done under two diﬀerent experimental conditions where diﬀerent types of
ﬁbrils are known to be formed. (A) (PG:G 1:10) 50 mM glycine pH 2.5; (B) (PG:G 1:15) 10 mM HCl pH 2.0, 7 mM Na2SO4. Inserts are phase
diagrams of the same experiments where pyrene emission at 470 nm is plotted versus normalized tryptophan ﬂuorescence.
Fig. 4. Phase diagrams for aggregation of glucagon at 0.063-0.25 g/l
glucagon (ratio 1:10 PG:G) pH 2.3, 16 mMNaCl. Pre type A ﬁbrils are
not formed at total glucagon concentrations below 0.25 g/l glucagon.
Here it shows that the bend in the phasediagram indicated with the
dashed arrow; disappears as the glucagon concentration goes down.
The bend is also visible in Fig. 3A and B at 0.5 g/l total glucagon. We
also suspect glycine to aﬀect the aggregation process, which is why the
pyrene excimer signals might look diﬀerent in the end products.
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glucagon, (1:5), and (1:10) PG:G ratios are a perfect match
and all show the characteristic signature of type B ﬁbrils
(Fig. S3).4. Discussion
We have shown that pyrene-labelling may be used to detect
pre-ﬁbrillar species. Excimer formation precedes ﬁbrillation by
several hours and culminates around the time when elongation
is most rapid. It is a characteristic feature of an obligate inter-
mediate preceding the end product that the rate of formationof the end product is directly proportional to the concentration
of the intermediate. This strongly suggests that the aggregate is
an obligate pre-ﬁbrillar species. Such species accumulates un-
der two diﬀerent ﬁbrillation conditions, namely glycine pH
2.5 as well as sodium sulfate pH 2. The ﬁbrils formed under
these two conditions are diﬀerent [15,17] and we cannot rule
out that the two pre-ﬁbrillar species are diﬀerent, since the
excimer assay cannot necessarily distinguish between two dif-
ferent oligomer types. However, in both cases an obligate
pre-ﬁbrillar intermediate appears to be involved. Note that
the species we detect in this way are not the ﬁbrillation nuclei
themselves. Since the formation of nuclei is the rate-determin-
ing step, these species will be relatively short-lived and will not
accumulate to any signiﬁcant extent. Rather, the detected spe-
cies are probably able to undergo a conformational conversion
in a subsequent step to generate such a nucleus capable of ra-
pid growth [7]. AFM studies have previously reported poten-
tial oligomeric glucagon species [3]. This provides an
additional, albeit indirect, support to our spectroscopic detec-
tion of oligomers.
Our data also identiﬁes pitfalls in our pyrene-labelling strat-
egy, namely the formation of non-ﬁbrillar aggregates at high
concentrations (>0.2 mg/ml) of pyrene-labelled glucagon. The
impact of a large and very hydrophobic moiety is particularly
dramatic when introduced into a relatively small peptide such
as glucagon, which is already disposed to form diﬀerent kinds
of aggregates depending on the conditions. Larger molecules
will be less sensitive to this perturbation as seen for the yeast
prion protein [14], but we still recommend that appropriate
controls be made or that the protein be diluted out with
non-labelled protein to reduce the risk of non-speciﬁc aggrega-
tion.
The excimer signal originating from the ﬁbrils formed as end
products here seems to vary with the type of ﬁbrils formed.
Additionally the type B ﬁbrils seem to be able to generate
two kinds of contact, one generating excimer signal (glycine ﬁ-
brils (Fig 3A)) and one not (pH 2.3 ﬁbrils (Fig. 4)). This may
reﬂect an underlying polymorphism which cannot be detected
Fig. 5. Model outlining the pathway from monomer to type B ﬁbril proposed based on the development of diﬀerent ﬂuorescence signals over time.
First monomers assemble to circular oligomers, they then become ﬁlled to appear as spheres, which through a transient ﬁbrillation nucleus forms
either pre type A ﬁbrils or type B ﬁbrils with varying excimer signal.
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probe to follow the aggregation process. Based on the various
ﬂuorescence changes described here we propose a model for
the rearrangement of the pre-ﬁbrillar specie to ﬁbril (Fig. 5).
This is based on previous reports on glucagon ﬁbrillation
[3,15], and the phase diagrams of excimer signals vs. trypto-
phan signals (Figs. 3 and 4).
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